Complications of sequential immunotherapy in metastatic melanoma
نویسندگان
چکیده
Background Advanced melanoma is associated with a poor prognosis. Targeted therapy and immunotherapy are mainstays of treatment. High-dose interleukin-2 (HD IL-2), interferon alfa-2b, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, and programmed cell death protein 1 (PD-1) inhibitors are approved immunotherapies. Genetically engineered T cells targeting melanoma antigens are currently under investigation. Patients with advanced melanoma are often exposed to multiple immunotherapies over their disease course. Adverse implications of sequential use of these therapies is not well described. Here we present a case of a patient with metastatic melanoma who developed rhabdomyolysis and vitiligo after various courses of immunotherapy.
منابع مشابه
Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment
Cutaneous melanoma arises from the malignant transformation of skin melanocytes; its incidence and mortality have been increasing steadily over the last 50 years, now representing 3% of total tumors. Once melanoma metastasizes, prognosis is somber and therapeutic options are limited. However, the discovery of prevalent BRAF mutations in at least 50% of melanoma tumors led to development of BRAF...
متن کاملDurable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy
We report 3 cases of durable complete response (CR) in patients with BRAF-mutated metastatic melanoma who were initially treated unsuccessfully with sequential immunotherapies (high dose interleukin 2 followed by ipilimumab with or without concurrent radiation therapy). After progression during or post immunotherapy, these patients were given BRAF inhibitor therapy and developed rapid CRs. Base...
متن کاملTargeted agents for the treatment of metastatic melanoma
In the last year, the armamentarium of melanoma therapeutics has radically changed. Recent discoveries in melanoma biology and immunology have led to novel therapeutics targeting known oncogenes and immunotherapeutic antibodies. Phase III clinical trials of these agents have reported measurable and meaningful benefits to patients with metastatic disease. In this article, we review recent findin...
متن کاملAcute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma
BACKGROUND The anti-Programmed Death receptor 1 (anti-PD-1) antibodies nivolumab and pembrolizumab are new treatments in metastatic melanoma. Immunotherapies are best known to be responsible for thrombotic microangiopathy. However, immune interstitial nephritis has been described in a patient treated by nivolumab and ipilimumab concomitantly, and three cases of granulomatous interstitial nephri...
متن کاملUncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma
Melanoma is a disease process which has been increasing in incidence over the past three decades and metastatic melanoma carries a poor prognosis. Through genetic studies of this disease, it has been determined that the BRAF V600 mutation plays a major role in the pathophysiology of the disease and this has led to the utilization of targeted therapy (BRAF and MEK inhibitors) in its treatment. O...
متن کامل